Breast
RTOG 0413/NSABP B-39: A Randomized Phase III Study of Conventional Whole Breast
Irradiation (WBI) versus Partial Breast Irradiation (PBI) for Women with Stage
0, I, or II Breast Cancer
RTOG 0974/NSABP B-43: A Phase III Clinical Trial Comparing Trastuzumab Given
Concurrently with Radiation Therapy and Radiation Therapy Alone for Women with
HER-2 Positive Ductal Carcinoma In Situ Resected by Lumpectomy.
Lung
RTOG 0538: CALGB 30610/Endorsed Study: Phase III Comparison of Thoracic
Radiotherapy Regimens in Patients with Limited Small Cell Lung Cancer Also
Receiving Cisplatin and Etoposide
RTOG 0813: Seamless Phase I/II Study of Stereotactic Lung Radiotherapy (SBRT)
for Early Stage, Centrally Located, Non-Small Cell Lung Cancer (NSCLC) in
Medically Inoperable Patients
RTOG 0937: Randomized Phase II Study Comparing Prophylactic Cranial Irradiation
Alone To Prophylactic Cranial Irradiation And Consolidative Extra-Cranial
Irradiation For Extensive Disease Small Cell Lung Cancer (ED-SCLC)
Jefferson/Genentech #OSI4327s: A Phase II Study of Erlotinib (Tarceva) and
hypofractionated thoracic radiotherapy for patients with advanced or inoperable
non-small lung cancer
Prostate
RTOG 0526: A Prospective Phase II Trial of Transperineal Ultrasound-Guided
Brachytherapy for Locally Recurrent Prostate Adenocarcinoma Following External
Beam Radiotherapy
RTOG 0534: A Phase III Trial of Short Term Androgen Deprivation With Pelvic
Lymph Node or Prostate Bed Only Radiotherapy (SPPORT) in Prostate Cancer
Patients With a Rising PSA After Radical Prostatectomy
RTOG 0622: A Phase II Trial of Samarium 153 Followed By Salvage Prostatic Fossa
3D-CRT or IMRT Irradiation In High-Risk, Clinically Non-Metastatic Prostate
Cancer after Radical Prostatectomy
RTOG 0815: A Phase III Prospective Randomized Trial of Dose-Escalated
Radiotherapy with or without Short-Term Androgen Deprivation Therapy for
Patients with Intermediate-Risk Prostate Cancer
RTOG 0924: Androgen Deprivation Therapy and High Dose Radiotherapy With or
Without Whole-Pelvic Radiotherapy in Unfavorable Intermediate or Favorable High
Risk Prostate Cancer: A Phase III Randomized Trial
Brain
RTOG 0837: Randomized, Phase II, Double-Blind, Placebo-Controlled Trial of
Conventional Chemoradiation and Adjuvant Temozolomide Plus Cediranib versus
Conventional Chemoradiation and Adjuvant Temozolomide Plus Placebo in Patients
with Newly Diagnosed Glioblastoma
RTOG 0933: A Phase II Trial of Hippocampal Avoidance During Whole Brain
Radiotherapy for Brain Metastases--RTOG CCOP Study
Bladder
RTOG 0524: A Phase I/II Trial of a Combination of Paclitaxel and Trastuzumab
With Daily Irradiation or Paclitaxel alone With Daily Irradiation Following
Transurethral Surgery for Non-Cystectomy Candidates With Muscle-Invasive Bladder
Gastrointestinal
RTOG 0436: A Phase III Trial Evaluating the Addition of Cetuximab to Paclitaxel,
Cisplatin, and Radiation for Patients With Esophageal Cancer Who Are Treated
Without Surgery
RTOG 0848: A Phase III Trial Evaluating both Erlotinib And Chemoradiation as
Adjuvant Treatment for Patients with Resected Head of Pancreas Adenocarcinoma
RTOG 1010: A Phase III Trial Evaluating the Addition of Trastuzumab to
Trimodality Treatment of Her2-Overexpressing Esophageal Adenocarcinoma
Head and Neck
RTOG 0920: A Phase III Study of Postoperative Radiation Therapy (IMRT) +/-
Cetuximab for Locally-Advanced Resected Head and Neck Cancer
RTOG 1016: Phase III Trial of Radiotherapy Plus Cetuximab Versus
Chemoradiotherapy in HPV-Associated Oropharynx Cancer
About Cancer Clinical Research:

The team of physicians at
Northeast Radiation Oncology Center (NROC) is dedicated to
providing the most advanced treatment and the highest standards
of care. One way we do this is by offering cancer patients in
Northeastern Pennsylvania the opportunity to participate in
cancer clinical research trials sponsored by the National Cancer
Institute (NCI). These trials are available through all our
NROC sites, so patients do not have to travel long distances to
benefit from state-of-the-art cancer therapies.
Cancer clinical trials are research studies conducted with patients to evaluate
new treatments. Each study is designed to answer specific medical
questions and to find new and better ways to help people with cancer.
Research trials sponsored by NCI are offered to patients only by experienced
physicians in accredited facilities such as NROC. People decide to enroll in a
clinical trial only after they have discussed the study thoroughly with their
physician and they have made an informed decision to participate.
In most
treatment studies, scientists seek to determine if new treatments are safe,
effective, and superior to standard treatments. These cancer studies look at
many types of treatments, such as new drugs or vaccines, new approaches to
surgery, radiation therapy or chemotherapy, or new combinations of these
treatments.
Other
studies seek to improve the quality of life for cancer patients. Or, they may
seek to find the most effective way to prevent a recurrence of cancer after
treatment.
Cancer
treatments currently available for patients often are the result of earlier
clinical trials. In turn, today’s standard treatments may be the basis for new
clinical trials to find better ways to treat cancer.
Still
other research studies, known as prevention trials, look at ways to prevent
cancer.
NROC Research
Accreditation:

The doctors
at NROC are accredited by the National Cancer Institute (NCI) to participate in
cancer research trials. This means they have access to the newest, most
advanced treatment protocols available in the country for cancer treatment.
Cancer
treatment facilities that offer such state-of-the-art NCI-sponsored research
must meet very high standards not demanded in non-participating institutions.
Patients who wish to benefit from these cancer clinical trials may do so only in
cancer centers such as NROC that are accredited by the National Cancer
Institute.
NROC Research
Experience:

NROC physicians
have participated as Principal Investigators in cancer research trials in
Northeastern Pennsylvania for over 20 years through the Radiation Therapy
Oncology Group (RTOG), sponsored by the National Cancer Institute. The NROC
research team has been recognized nationally for the outstanding quality of its
research, and hundreds of patients have participated and benefited from these
research studies.
Patient Research
Participation at NROC:

Clinical trials are available for most types and
stages of cancer. The doctors at NROC determine whether patients are eligible
to participate in these clinical research trials.
For
eligible patients, the decision to participate in a trial ultimately rests with
them. Patients participate only after they have received comprehensive
information about the trial and have voluntarily decided to be part of the study
that is applicable to their case.
For
more information about clinical trials,
click here.
NROC Research
Network:

Most of the cancer
trials available through NROC are offered through the Radiation Therapy
Oncology Group (RTOG). NROC physicians have participated in
RTOG research
studies for nearly 20 years.
RTOG is
a multi-institutional cooperative cancer research organization funded by the
National Cancer Institute (NCI). RTOG, which is composed of 250 major research
groups such as NROC, has been the leader in radiation therapy cancer research
for 30 years in the United States and Canada. Click
here for more information about RTOG.
NROC
physicians also collaborate with physicians at the Thomas Jefferson University
Hospital Cancer Network for RTOG research. For more information about the
radiation therapy clinical trials available through the Jefferson Cancer
Network, click here.